Summary of Study ST000789

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000574. The data can be accessed directly via it's Project DOI: 10.21228/M8GD58 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST000789
Study TitleIdentifying metabolic adaptations characteristic of multiple myeloma cells via mass spectrometry-based metabolite profiling from (CD138+ Plasma Cells)
Study SummaryWill be assessing the untargeted metabolomic profiles of high risk versus low risk smoldering myeloma patients based on peripheral blood plasma, bone marrow plasma and Cd138+ plasma cells. Cd138+ plasma cells ms5974
Institute
Mayo Clinic
Last NameGonsalves
First NameWilson
Address200 First St. SW, Rochester, Minnesota, 55905, USA
Emailgonsalves.wilson@mayo.edu
Phone507-266-0792
Submit Date2017-07-11
Analysis Type DetailLC-MS
Release Date2019-07-17
Release Version1
Wilson Gonsalves Wilson Gonsalves
https://dx.doi.org/10.21228/M8GD58
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000574
Project DOI:doi: 10.21228/M8GD58
Project Title:Mayo Pilot and Feasibility: Identifying metabolic adaptations characteristic of multiple myeloma cells via mass spectrometry-based metabolite profiling
Project Summary:Multiple myeloma (MM) is a clonal plasma cell malignancy that remains incurable in most afflicted patients. It can be preceded by an asymptomatic, premalignant stage known as smoldering multiple myeloma (SMM) that does not require therapy but has an increased life-long risk of progression to MM. However, one-third of SMM patients are “high risk” for imminent progression to MM within two years of diagnosis compared to the remainder of SMM patients who continue on an indolent asymptomatic course for several years. The diagnosis of MM cannot be made until they experience overt end-organ damage such as renal failure, lytic bone destruction, anemia and hypercalcemia. Currently, we lack sensitive biomarkers that can identify all SMM patients at high risk of progression to MM. Being able to identify high risk SMM patients could allow us to initiate systemic chemotherapy before they progress to MM. Cancer cells undergo distinct metabolic adaptations to meet the augmented cellular demand for energy and nutrients created by their increased rates of cellular proliferation. The presence of an altered cellular metabolism in clonal PCs from MM patients and its role as an essential factor in the progression of SMM to MM is unknown. We hypothesize that the clonal PCs in high risk SMM patients likely have an altered metabolic phenotype similar to those present in MM patients but different when compared to clonal PCs in the remainder of the SMM patients whose clinical course remains indolent. Thus, two specific aims are proposed in this study: Aim 1 will verify if there are differences in the regulation of the metabolic pathways in clonal PCs from MM patients compared to normal PCs from healthy patients; Aim 2 will assess whether the clonal PCs from high risk SMM patients bear a distinct metabolic phenotype compared to clonal PCs from standard risk SMM patients.
Institute:Mayo Clinic
Last Name:Gonsalves
First Name:Wilson
Address:200 First St. SW, Rochester, Minnesota, 55905, USA
Email:gonsalves.wilson@mayo.edu
Phone:507-266-0792

Subject:

Subject ID:SU000814
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id groups rep
SA043407philic_16mar16-014-r001Quick Progress 1
SA043408nhilic-17mar16-007Quick Progress 1
SA043409nhilic-17mar16-009Quick Progress 1
SA043410nhilic_17mar16-014Quick Progress 1
SA043411philic_16mar16-011-r001Quick Progress 1
SA043412nhilic-17mar16-006Quick Progress 1
SA043413nhilic-17mar16-011Quick Progress 1
SA043414nhilic-17mar16-004Quick Progress 1
SA043415pC18-15mar16-020Quick Progress 1
SA043416pC18-15mar16-019Quick Progress 1
SA043417philic_16mar16-016-r001Quick Progress 1
SA043418pC18-15mar16-022Quick Progress 1
SA043419nhilic-17mar16-003Quick Progress 1
SA043420nhilic_17mar16-016Quick Progress 1
SA043421nhilic_17mar16-017Quick Progress 1
SA043422philic_16mar16-003-r001Quick Progress 1
SA043423philic_16mar16-009-r001Quick Progress 1
SA043424philic_16mar16-004-r001Quick Progress 1
SA043425philic_16mar16-007-r001Quick Progress 1
SA043426philic_16mar16-006-r001Quick Progress 1
SA043427philic_16mar16-001-r001Quick Progress 1
SA043428nhilic_17mar16-025Quick Progress 1
SA043429nhilic_17mar16-020Quick Progress 1
SA043430nhilic_17mar16-019Quick Progress 1
SA043431nC18-16mar16-001-r001Quick Progress 1
SA043432nhilic_17mar16-022Quick Progress 1
SA043433nhilic_17mar16-023Quick Progress 1
SA043434pC18-15mar16-016Quick Progress 1
SA043435nhilic-17mar16-001Quick Progress 1
SA043436philic_16mar16-025-r001Quick Progress 1
SA043437philic_16mar16-023-r001Quick Progress 1
SA043438pC18-15mar16-004Quick Progress 1
SA043439philic_16mar16-020-r001Quick Progress 1
SA043440nC18-16mar16-014Quick Progress 1
SA043441pC18-15mar16-001Quick Progress 1
SA043442nC18-16mar16-006Quick Progress 1
SA043443nC18-16mar16-019Quick Progress 1
SA043444philic_16mar16-022-r001Quick Progress 1
SA043445nC18-16mar16-022Quick Progress 1
SA043446nC18-16mar16-016Quick Progress 1
SA043447pC18-15mar16-006Quick Progress 1
SA043448nC18-16mar16-004-r001Quick Progress 1
SA043449pC18-15mar16-014Quick Progress 1
SA043450philic_16mar16-017-r001Quick Progress 1
SA043451philic_16mar16-019-r001Quick Progress 1
SA043452nC18-16mar16-009Quick Progress 1
SA043453pC18-15mar16-009Quick Progress 1
SA043454philic_16mar16-023-r002Quick Progress 2
SA043455philic_16mar16-003-r002Quick Progress 2
SA043456philic_16mar16-022-r002Quick Progress 2
SA043457philic_16mar16-001-r002Quick Progress 2
SA043458philic_16mar16-009-r002Quick Progress 2
SA043459philic_16mar16-004-r002Quick Progress 2
SA043460philic_16mar16-025-r002Quick Progress 2
SA043461philic_16mar16-006-r002Quick Progress 2
SA043462philic_16mar16-017-r002Quick Progress 2
SA043463philic_16mar16-014-r002Quick Progress 2
SA043464philic_16mar16-019-r002Quick Progress 2
SA043465philic_16mar16-011-r002Quick Progress 2
SA043466philic_16mar16-020-r002Quick Progress 2
SA043467philic_16mar16-007-r002Quick Progress 2
SA043468philic_16mar16-016-r002Quick Progress 2
SA043469philic_16mar16-021-r001Slow Progress 1
SA043470philic_16mar16-015-r001Slow Progress 1
SA043471philic_16mar16-018-r001Slow Progress 1
SA043472philic_16mar16-013-r001Slow Progress 1
SA043473philic_16mar16-012-r001Slow Progress 1
SA043474philic_16mar16-024-r001Slow Progress 1
SA043475philic_16mar16-010-r001Slow Progress 1
SA043476philic_16mar16-008-r001Slow Progress 1
SA043477nhilic_17mar16-021Slow Progress 1
SA043478pC18-15mar16-008Slow Progress 1
SA043479pC18-15mar16-005Slow Progress 1
SA043480pC18-15mar16-002Slow Progress 1
SA043481pC18-15mar16-010Slow Progress 1
SA043482pC18-15mar16-012Slow Progress 1
SA043483pC18-15mar16-015Slow Progress 1
SA043484pC18-15mar16-013Slow Progress 1
SA043485nC18-16mar16-021Slow Progress 1
SA043486nC18-16mar16-015Slow Progress 1
SA043487nC18-16mar16-007Slow Progress 1
SA043488nC18-16mar16-005-r001Slow Progress 1
SA043489nC18-16mar16-002-r001Slow Progress 1
SA043490nC18-16mar16-008Slow Progress 1
SA043491nC18-16mar16-010Slow Progress 1
SA043492nC18-16mar16-013Slow Progress 1
SA043493nC18-16mar16-012Slow Progress 1
SA043494pC18-15mar16-021Slow Progress 1
SA043495pC18-15mar16-018Slow Progress 1
SA043496nhilic_17mar16-015Slow Progress 1
SA043497nhilic-17mar16-012Slow Progress 1
SA043498nhilic_17mar16-018Slow Progress 1
SA043499nhilic_17mar16-024Slow Progress 1
SA043500philic_16mar16-005-r001Slow Progress 1
SA043501philic_16mar16-002-r001Slow Progress 1
SA043502nhilic-17mar16-010Slow Progress 1
SA043503nhilic_17mar16-013Slow Progress 1
SA043504nhilic-17mar16-002Slow Progress 1
SA043505nhilic-17mar16-005Slow Progress 1
SA043506nhilic-17mar16-008Slow Progress 1
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 110

Collection:

Collection ID:CO000808
Collection Summary:In order to analyze the metabolites of clonal PCs (intracellular) and BM plasma (extracellular) separately, they have to be separated out from the BM samples. Thus, upon acquiring the BM samples from patients they will be placed in centrifuged at 2500 rpm for 10 minutes to separate out the plasma from the cellular fraction. The separated BM plasma is then stored in separate vials and snap frozen under liquid nitrogen for 20 seconds before storing at -80οC for further analysis. The leftover cellular component present as a pellet will be washed and reconstituted with an equal volume of RPMI 1640 medium. Erythrocytes are lysed using ammonium chloride lysing solution. After incubation on ice for 5 min, the cell suspension is diluted with RPMI medium. The cells are again pelleted by centrifugation and then suspended in RoboSep buffer (250ml PBS, 2% BSA, 1mM EDTA). The clonal CD138 positive PCs are purified using positive selection by mixing the cells with a CD138 positive selection cocktail and anti-CD138 magnetic-activated cell separation microbeads (ROBOSEP™ cell separation system, StemCell Technologies Inc) in the automated RoboSep cell separation system. The purified samples containing only CD138 positive cells are re‐suspended and then centrifuged to form a cell pellet. The goal will be to obtain at least 1-2 x 107 clonal PCs per sample. The cell pellet will be snap frozen under liquid nitrogen for 20 seconds before storing at -80οC for further analysis. Both the BM plasma samples as well as the clonal PCs pellet will be provided to the metabolomics core for sample preparation for LC-MS analysis. For Aim 2, we will be using stored BM samples from SMM patients that have already had their BM plasma and clonal PCs separated from each other and stored at -80οC. It is important to note that all these samples were collected and frozen in a timely manner. Furthermore consistency in sample collection, storage and processing is imperative for the optimal conduct of metabolomics-based experiments. This ensures that all samples being analyzed and compared with each other would have been manipulated similarly, limiting any handling biases. All patient samples in the Predolin Foundation Biobank were collected and stored by following a standardized operating procedure. BM samples were processed for BM plasma separation and clonal PCs enrichment but were then immediately snap frozen for storage at -80οC within approximately 3 hours of collection from the patient. All samples were collected in patients who have been fasting for at least 6 to 8 hours prior. To further ensure consistency in our analysis of this study, we will only use samples that have never been thawed since initial storage to preserve the stability of the metabolites originally present in the samples.
Sample Type:Bone marrow

Treatment:

Treatment ID:TR000828
Treatment Summary:We will use matched BM plasma and purified clonal marrow PCs from the BM samples of SMM patients collected at the time of their diagnosis and stored within the Mayo Clinic Predolin Foundation Biobank. We will select BM samples from patients with SMM who progressed to MM within 2 years of their samples being collected and stored; this will constitute the high risk SMM group. We will also select BM samples from SMM patients who have not progressed to MM within at least 2 years of follow up of their samples being collected and stored; this will constitute the standard risk SMM group. The strength of this approach is that we will utilize stored SMM samples from one of the most comprehensively characterized monoclonal gammopathy biobanks available. Secondly, all samples will be obtained from collection dates at least 2 years prior in order to ensure adequate follow-up time to assess their current clinical status. This would avoid the need to prospectively collect samples from SMM patients and clinically follow them for a number of years before we are able to gauge who were clinically high or standard risk for progression. There are over 700 SMM patients who have had their BM samples collected and stored in the biobank from 1996 to 2013; more than half these patients have progressed to MM.

Sample Preparation:

Sampleprep ID:SP000821
Sampleprep Summary:The metabolite profiling as well as sample preparations will be undertaken at the Mayo Clinic Metabolomics Resource Core. The matched BM plasma and clonal PCs pellets from the stored patient samples will undergo metabolite extraction and analysis by LC-MS. They will be deproteinized with cold methanol (1:4 ratio) and centrifuged at 15,000 g for 20 minutes at 4οC. The supernatants will be divided into 2 aliquots and dried down under a stream of nitrogen for 90 minutes and stored at -20C until ready for analysis. These samples will undergo preparation for metabolite separation and analysis on a Time-of-Flight (TOF) Mass Spectrometer (Agilent Technologies 6220 TOF) coupled with an Ultra High Pressure Liquid Chromatograph (Waters Acquity). The dried metabolites will be re‐suspended in H2O/acetonitrile solution containing injection standards. Profiling data will be acquired under both positive and negative electrospray ionization modes separately over a scan range of 50 - 1200 m/z at a resolution of 10,000. Metabolite separation will be achieved using two columns of differing polarity, a hydrophilic interaction column (HILIC, ethylene-bridged hybrid 2.1 x 150 mm, 1.7 mm; Waters) and a reversed-phase C18 column (high-strength silica 2.1 x 150 mm, 1.8 mm; Waters). For positive ion detection, mobile phase A will contain 100% water with 0.1% formic acid and mobile phase B will contain 100% methanol with 0.1% formic acid. For negative ion detection, formic acid will be replaced with 0.1% ammonium bicarbonate. For each column, the run time will be 20 min using a flow rate of 400 microL/min. A total of four runs per sample will be performed to give maximum coverage of metabolites. Samples will be injected in triplicate with blank injections between samples. Quality control samples, made up of a subset of samples from the study will be injected several times during a run.

Combined analysis:

Analysis ID AN001254 AN001255 AN001256 AN001257
Analysis type MS MS MS MS
Chromatography type Reversed phase Reversed phase HILIC HILIC
Chromatography system Agilent 1290 Infinity Agilent 1290 Infinity Agilent 1290 Infinity Agilent 1290 Infinity
Column Waters Acquity HSS C18 (150 x 2.1mm,1.8um) Waters Acquity HSS C18 (150 x 2.1mm,1.8um) Waters Acquity BEH Amide (150 x 2.1mm,1.7um) Waters Acquity BEH Amide (150 x 2.1mm,1.7um)
MS Type ESI ESI ESI ESI
MS instrument type QTOF QTOF QTOF QTOF
MS instrument name Agilent 6550 QTOF Agilent 6550 QTOF Agilent 6550 QTOF Agilent 6550 QTOF
Ion Mode POSITIVE NEGATIVE POSITIVE NEGATIVE
Units intensity intensity intensity intensity

Chromatography:

Chromatography ID:CH000874
Instrument Name:Agilent 1290 Infinity
Column Name:Waters Acquity HSS C18 (150 x 2.1mm,1.8um)
Chromatography Type:Reversed phase
  
Chromatography ID:CH000875
Instrument Name:Agilent 1290 Infinity
Column Name:Waters Acquity BEH Amide (150 x 2.1mm,1.7um)
Chromatography Type:HILIC

MS:

MS ID:MS001147
Analysis ID:AN001254
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
Ion Mode:POSITIVE
  
MS ID:MS001148
Analysis ID:AN001255
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
Ion Mode:NEGATIVE
  
MS ID:MS001149
Analysis ID:AN001256
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
Ion Mode:POSITIVE
  
MS ID:MS001150
Analysis ID:AN001257
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
Ion Mode:NEGATIVE
  logo